Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study.
Amandeep SinghArka DeMini P SinghSahaj RathiNipun VermaMadhumita PremkumarSunil TanejaAjay DusejaVirendra SinghPublished in: Digestive diseases and sciences (2022)
Our preliminary data suggest that ChAdOx1-nCOV is safe with high seroconversion rates in patients with cirrhosis.